Hallmarks of Cancer: Asia

As one of the most investigated areas in biomedical research, the cancer field is rapidly advancing by translating biological insights towards better detection and therapeutics, including molecular classifications as well as immunotherapies. In the era of the genetically informed, emerging concepts in cancer biology and oncology research are colliding into precision medicine. In order to accelerate the development of personalized cancer therapies and further translate fundamental discoveries into the clinic, there must be open lines of communication at the interface between the lab and the clinic.

Our goal in organizing this Cell Symposium, Hallmarks of Cancer: Asia, is to convene global leaders in the cancer research arena to enhance our understanding of the key aspects of cancer and how to promote translation of this knowledge into the development of targeted therapeutics. We aim to provide a high-impact, high-profile forum for exchanging ideas and establishing a dialogue amongst clinicians, scientists and drug development companies.

As the inaugural Cell Symposium in Asia, we hope to stimulate new networks between scientists and clinicians within Asia and beyond to spark new and fruitful inter-continental collaborations. We look forward to seeing you in Beijing in November 2014!

Symposium themes:

Understanding cancer hallmarks - new frontiers
Cancer hallmarks as therapeutic targets
Tumor immunology and immunotherapy
Clinical progress and obstacles
Managing cancer in the “omics” era
+ show speakers and program
Confirmed Speakers

Keynote Speakers
James P. Allison, MD Anderson Cancer Center, USA
David Baltimore, California Institute of Technology, USA
Zhu Chen, Shanghai Jiao Tong University, China
Alan Ashworth, The Institute of Cancer Research, London, UK
J. Michael Bishop, University of California San Francisco, USA
Xuetao Cao, Chinese Academy of Medical Sciences, China (organizer)
Suzanne Cory, Walter & Eliza Hall Institute of Medical Research, Australia
Lisa Coussens, Oregon Health & Science University, USA
James Downing, St. Jude Children’s Research Hospital, USA
Gou Young Koh, Korea Advanced Institute of Science and Technology, South Korea
Guido Kroemer, INSERM, France
Thomas James Lynch, Yale University, USA
Tak Wah Mak, University of Toronto, Canada
Alberto Mantovani, Istituto Clinico Humanitas, Italy
Stefan Pfister, Deutsches Krebsforschungszentrum, (DKFZ), Germany
Xiaodong Wang, National Institute of Biological Sciences, China
Paul Workman, The Institute of Cancer Research, London, UK

9 Nov - 11 Nov 2014
meeting website